Solutions
About Us
Insights
Careers

Axillary clearance and chemotherapy rates in ER+HER2- breast cancer: secondary analysis of the SENOMAC trial. Tvedskov TF, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Bagge RO, Reimer T, Sund M, Rydén L, Christiansen P, de Boniface J; SENOMAC Trialists’ Group. Lancet Reg Health Eur. 2024

Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial. de Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Olofsson Bagge R, Reimer T, Sund M, Christiansen P, Rydén L, Filtenborg Tvedskov T; SENOMAC Trialists’ Group. Lancet Oncol. 2024

Establishing the minimal clinically important difference of the Brief Fatigue Inventory for brain or CNS cancer patients undergoing radiotherapy. Gunn HJ, Zaniletti I, Breen WG, Leavitt T, Bogan A, Mahajan A, Brown PD, Yan E, Vora SA, Merrell KW, Ashman JB, Peterson JL, Leenstra JL, Wilson ZC, Laughlin BS, Laack NN, DeWees TA. Neurooncol Pract. 2024

TAZ downregulated ANXA1 expression to modulate myeloma cell interactions with bone marrow mesenchymal stromal cells. Abegunde SO, Grieve S, Reiman T. Exp Hematol. 2024

Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis. O’Dwyer R, Musat MG, Gulas I, Hubscher E, Moradian H, Guenther S, Kearney M, Sridhar SS. Clin Genitourin Cancer. 2024

Prediction of High Nodal Burden in Patients With Sentinel Node-Positive Luminal ERBB2-Negative Breast Cancer. Skarping I, Bendahl PO, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Christiansen P, Filtenborg Tvedskov T, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Vrou Offersen B, Olofsson Bagge R, Reimer T, Sund M, Rydén L, de Boniface J. JAMA Surg. 2024

Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces temperature-evoked pain in patients with peripheral neuropathic pain with sensory hypersensitivity, a randomized, double-blind, placebo-controlled, crossover study. Miclescu A, Karlsten R, Lönnstedt I, Halldin MM, Segerdahl M. Scand J Pain. 2025

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. Sweis RF, Chatta GS, Jain RK, Moon H, Delacroix SE, Fang A, D’Amico L, Kask AS, Cheever MA, Fling S, Sharon E, Lacroix A, Kaiser JC, Pachynski RK, Yu EY. Clin Cancer Res. 2025

Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison. Anwer F, Lan T, Dolph M, Moradian H, Slaff S, Shih YH, Tang D. Future Oncol. 2025

Recurrence of Cardiovascular Events After an Acute Myocardial Infarction in Patients with Multivessel Disease and Associated Healthcare Costs: A German Claims Data Analysis. Starry A, Picker N, Galduf J, Maywald U, Dittmar A, Spitzer SG. Pharmacoeconomics. 2025